Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 36. More products

IRBESARTAN & HYDROCHLOROTHIAZIDE

All products: general benefit

Other products in the same Health Canada class (C09DA) — coverage varies; not interchangeable

  • Candesartan cilexetil + hydrochlorothiazide (Atacand Plus): general benefit
  • Hydrochlorothiazide + losartan (Hyzaar): general benefit
  • Hydrochlorothiazide + olmesartan medoxomil (Olmetec Plus): general benefit
  • Hydrochlorothiazide + telmisartan (Micardis Plus): general benefit
  • Hydrochlorothiazide + valsartan (Diovan-HCT): general benefit
  • Eprosartan + hydrochlorothiazide (Teveten Plus): general benefit

1 more in the class list below

Avalide · DIN 02241818 · 150mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists AVALIDE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Avalide · DIN 02241818 Manufacturer: Sanofi Aventis Pharma; listing date 2001-03-07 Health Canada: Marketed since 2007-06-11 · brand AVALIDE · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, IRBESARTAN 150 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65483 · Verify on the e-Formulary ↗ (DIN 02241818)

Source record
DIN 02241818: Avalide Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id SAV Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.3710; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241818 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65483
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387646 · $0.2281 Auro-Irbesartan HCT · DIN 02447878 · $0.2281 Co Irbesartan/HCT · DIN 02357399 · $0.2281 Irbesartan HCT · DIN 02385317 · $0.2281 Irbesartan/HCTZ · DIN 02372886 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328518 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Sandoz Irbesartan HCT · DIN 02337428 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330512 · $0.2281
Shortage status: resolved shortage (ended 2025-12-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241818
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Irbesartan HCT · DIN 02385317 · 150mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Irbesartan HCT · DIN 02385317 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-06-10 · brand IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, IRBESARTAN 150 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Irbesartan HCT: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87095 · Verify on the e-Formulary ↗ (DIN 02385317)

Source record
DIN 02385317: Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id SIV Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385317 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87095
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387646 · $0.2281 Auro-Irbesartan HCT · DIN 02447878 · $0.2281 Avalide · DIN 02241818 · $0.2281 Co Irbesartan/HCT · DIN 02357399 · $0.2281 Irbesartan/HCTZ · DIN 02372886 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328518 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Sandoz Irbesartan HCT · DIN 02337428 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330512 · $0.2281
Shortage status: resolved shortage (ended 2020-11-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385317
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Irbesartan-HCTZ · DIN 02328518 · 150mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Irbesartan-HCTZ · DIN 02328518 Manufacturer: Pharmascience Inc.; listing date 2011-08-04 Health Canada: Marketed since 2011-03-24 · brand PMS-IRBESARTAN-HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 150 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Irbesartan-HCTZ: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81403 · Verify on the e-Formulary ↗ (DIN 02328518)

Source record
DIN 02328518: PMS-Irbesartan-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id PMS Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02328518 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81403
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387646 · $0.2281 Auro-Irbesartan HCT · DIN 02447878 · $0.2281 Avalide · DIN 02241818 · $0.2281 Co Irbesartan/HCT · DIN 02357399 · $0.2281 Irbesartan HCT · DIN 02385317 · $0.2281 Irbesartan/HCTZ · DIN 02372886 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Sandoz Irbesartan HCT · DIN 02337428 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330512 · $0.2281
Shortage status: active shortage (reported 2026-07-21, estimated to end 2027-01-31, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02328518
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Irbesartan HCT · DIN 02337428 · 150mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Irbesartan HCT · DIN 02337428 Manufacturer: Sandoz Canada Inc.; listing date 2011-08-04 Health Canada: Marketed since 2011-03-21 · brand SANDOZ IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, IRBESARTAN 150 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Irbesartan HCT: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82301 · Verify on the e-Formulary ↗ (DIN 02337428)

Source record
DIN 02337428: Sandoz Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id SDZ Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02337428 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82301
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387646 · $0.2281 Auro-Irbesartan HCT · DIN 02447878 · $0.2281 Avalide · DIN 02241818 · $0.2281 Co Irbesartan/HCT · DIN 02357399 · $0.2281 Irbesartan HCT · DIN 02385317 · $0.2281 Irbesartan/HCTZ · DIN 02372886 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328518 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330512 · $0.2281
Shortage status: active shortage (reported 2026-06-29, estimated to end 2026-10-09, last updated 2026-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337428
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Irbesartan HCTZ · DIN 02330512 · 150mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Irbesartan HCTZ · DIN 02330512 Manufacturer: Teva Canada Limited; listing date 2011-08-04 Health Canada: Marketed since 2018-06-13 · brand TEVA-IRBESARTAN HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 150 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Irbesartan HCTZ: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81624 · Verify on the e-Formulary ↗ (DIN 02330512)

Source record
DIN 02330512: Teva-Irbesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id TEV Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02330512 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81624
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387646 · $0.2281 Auro-Irbesartan HCT · DIN 02447878 · $0.2281 Avalide · DIN 02241818 · $0.2281 Co Irbesartan/HCT · DIN 02357399 · $0.2281 Irbesartan HCT · DIN 02385317 · $0.2281 Irbesartan/HCTZ · DIN 02372886 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328518 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Sandoz Irbesartan HCT · DIN 02337428 · $0.2281
Shortage status: discontinued (2025-06-16, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330512
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Avalide · DIN 02241819 · 300mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists AVALIDE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Avalide · DIN 02241819 Manufacturer: Sanofi Aventis Pharma; listing date 2001-03-07 Health Canada: Marketed since 2007-05-14 · brand AVALIDE · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 300 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65484 · Verify on the e-Formulary ↗ (DIN 02241819)

Source record
DIN 02241819: Avalide Raw flags: chronicUseMed=Y, sec3=Y Item: 240800243; group id 331; item number 0741; lccId None; manufacturer id SAV Source form: Tab; strength: 300mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.3710; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241819 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65484
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387654 · $0.2281 Auro-Irbesartan HCT · DIN 02447886 · $0.2281 Co Irbesartan/HCT · DIN 02357402 · $0.2281 Irbesartan HCT · DIN 02385325 · $0.2281 Irbesartan/HCTZ · DIN 02372894 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418231 · $0.2281 Mint Irbesartan/HCTZ · DIN 02393018 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328526 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363216 · $0.2281 Sandoz Irbesartan HCT · DIN 02337436 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330520 · $0.2281
Shortage status: resolved shortage (ended 2022-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241819
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Irbesartan HCT · DIN 02385325 · 300mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Irbesartan HCT · DIN 02385325 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-06-12 · brand IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, IRBESARTAN 300 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Irbesartan HCT: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87096 · Verify on the e-Formulary ↗ (DIN 02385325)

Source record
DIN 02385325: Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800243; group id 331; item number 0741; lccId None; manufacturer id SIV Source form: Tab; strength: 300mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87096
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387654 · $0.2281 Auro-Irbesartan HCT · DIN 02447886 · $0.2281 Avalide · DIN 02241819 · $0.2281 Co Irbesartan/HCT · DIN 02357402 · $0.2281 Irbesartan/HCTZ · DIN 02372894 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418231 · $0.2281 Mint Irbesartan/HCTZ · DIN 02393018 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328526 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363216 · $0.2281 Sandoz Irbesartan HCT · DIN 02337436 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330520 · $0.2281
Shortage status: resolved shortage (ended 2020-11-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385325
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Irbesartan HCT · DIN 02385333 · 300mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Irbesartan HCT · DIN 02385333 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-06-10 · brand IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, IRBESARTAN 300 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Irbesartan HCT: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2184 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87097 · Verify on the e-Formulary ↗ (DIN 02385333)

Source record
DIN 02385333: Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800263; group id 331; item number 0742; lccId None; manufacturer id SIV Source form: Tab; strength: 300mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2184; ministry $0.2184 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385333 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87097
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387662 · $0.2184 Auro-Irbesartan HCT · DIN 02447894 · $0.2184 Avalide · DIN 02280213 · not recorded Co Irbesartan/HCT · DIN 02357410 · $0.2184 Irbesartan/HCTZ · DIN 02372908 · $0.2184 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418258 · $0.2184 Mint Irbesartan/HCTZ · DIN 02393026 · $0.2184 PMS-Irbesartan-HCTZ · DIN 02328534 · $0.2184 Ran-Irbesartan HCTZ · DIN 02363224 · $0.2184 Sandoz Irbesartan HCT · DIN 02337444 · $0.2184 Teva-Irbesartan HCTZ · DIN 02330539 · $0.2184
Shortage status: resolved shortage (ended 2020-11-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385333
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Irbesartan-HCTZ · DIN 02328526 · 300mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Irbesartan-HCTZ · DIN 02328526 Manufacturer: Pharmascience Inc.; listing date 2011-08-04 Health Canada: Marketed since 2011-03-24 · brand PMS-IRBESARTAN-HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 300 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Irbesartan-HCTZ: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81404 · Verify on the e-Formulary ↗ (DIN 02328526)

Source record
DIN 02328526: PMS-Irbesartan-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800243; group id 331; item number 0741; lccId None; manufacturer id PMS Source form: Tab; strength: 300mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02328526 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81404
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387654 · $0.2281 Auro-Irbesartan HCT · DIN 02447886 · $0.2281 Avalide · DIN 02241819 · $0.2281 Co Irbesartan/HCT · DIN 02357402 · $0.2281 Irbesartan HCT · DIN 02385325 · $0.2281 Irbesartan/HCTZ · DIN 02372894 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418231 · $0.2281 Mint Irbesartan/HCTZ · DIN 02393018 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363216 · $0.2281 Sandoz Irbesartan HCT · DIN 02337436 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330520 · $0.2281
Shortage status: active shortage (reported 2022-11-14, estimated to end 2026-12-01, last updated 2025-08-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02328526
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Irbesartan-HCTZ · DIN 02328534 · 300mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Irbesartan-HCTZ · DIN 02328534 Manufacturer: Pharmascience Inc.; listing date 2011-08-04 Health Canada: Marketed since 2011-03-24 · brand PMS-IRBESARTAN-HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 300 MG, HYDROCHLOROTHIAZIDE 25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Irbesartan-HCTZ: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2184 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81405 · Verify on the e-Formulary ↗ (DIN 02328534)

Source record
DIN 02328534: PMS-Irbesartan-HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800263; group id 331; item number 0742; lccId None; manufacturer id PMS Source form: Tab; strength: 300mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2184; ministry $0.2184 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02328534 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81405
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387662 · $0.2184 Auro-Irbesartan HCT · DIN 02447894 · $0.2184 Avalide · DIN 02280213 · not recorded Co Irbesartan/HCT · DIN 02357410 · $0.2184 Irbesartan HCT · DIN 02385333 · $0.2184 Irbesartan/HCTZ · DIN 02372908 · $0.2184 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418258 · $0.2184 Mint Irbesartan/HCTZ · DIN 02393026 · $0.2184 Ran-Irbesartan HCTZ · DIN 02363224 · $0.2184 Sandoz Irbesartan HCT · DIN 02337444 · $0.2184 Teva-Irbesartan HCTZ · DIN 02330539 · $0.2184
Shortage status: anticipated shortage (last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02328534
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Irbesartan HCT · DIN 02337436 · 300mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Irbesartan HCT · DIN 02337436 Manufacturer: Sandoz Canada Inc.; listing date 2011-08-04 Health Canada: Marketed since 2011-03-21 · brand SANDOZ IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, IRBESARTAN 300 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Irbesartan HCT: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82302 · Verify on the e-Formulary ↗ (DIN 02337436)

Source record
DIN 02337436: Sandoz Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800243; group id 331; item number 0741; lccId None; manufacturer id SDZ Source form: Tab; strength: 300mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02337436 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82302
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387654 · $0.2281 Auro-Irbesartan HCT · DIN 02447886 · $0.2281 Avalide · DIN 02241819 · $0.2281 Co Irbesartan/HCT · DIN 02357402 · $0.2281 Irbesartan HCT · DIN 02385325 · $0.2281 Irbesartan/HCTZ · DIN 02372894 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418231 · $0.2281 Mint Irbesartan/HCTZ · DIN 02393018 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328526 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363216 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330520 · $0.2281
Shortage status: resolved shortage (ended 2025-06-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337436
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Irbesartan HCT · DIN 02337444 · 300mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Irbesartan HCT · DIN 02337444 Manufacturer: Sandoz Canada Inc.; listing date 2011-08-04 Health Canada: Marketed since 2011-03-21 · brand SANDOZ IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, IRBESARTAN 300 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Irbesartan HCT: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2184 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82303 · Verify on the e-Formulary ↗ (DIN 02337444)

Source record
DIN 02337444: Sandoz Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800263; group id 331; item number 0742; lccId None; manufacturer id SDZ Source form: Tab; strength: 300mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2184; ministry $0.2184 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02337444 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82303
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387662 · $0.2184 Auro-Irbesartan HCT · DIN 02447894 · $0.2184 Avalide · DIN 02280213 · not recorded Co Irbesartan/HCT · DIN 02357410 · $0.2184 Irbesartan HCT · DIN 02385333 · $0.2184 Irbesartan/HCTZ · DIN 02372908 · $0.2184 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418258 · $0.2184 Mint Irbesartan/HCTZ · DIN 02393026 · $0.2184 PMS-Irbesartan-HCTZ · DIN 02328534 · $0.2184 Ran-Irbesartan HCTZ · DIN 02363224 · $0.2184 Teva-Irbesartan HCTZ · DIN 02330539 · $0.2184
Shortage status: resolved shortage (ended 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337444
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Irbesartan HCTZ · DIN 02330520 · 300mg & 12.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Irbesartan HCTZ · DIN 02330520 Manufacturer: Teva Canada Limited; listing date 2011-08-04 Health Canada: Marketed since 2018-06-13 · brand TEVA-IRBESARTAN HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 300 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Irbesartan HCTZ: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81625 · Verify on the e-Formulary ↗ (DIN 02330520)

Source record
DIN 02330520: Teva-Irbesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800243; group id 331; item number 0741; lccId None; manufacturer id TEV Source form: Tab; strength: 300mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02330520 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81625
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387654 · $0.2281 Auro-Irbesartan HCT · DIN 02447886 · $0.2281 Avalide · DIN 02241819 · $0.2281 Co Irbesartan/HCT · DIN 02357402 · $0.2281 Irbesartan HCT · DIN 02385325 · $0.2281 Irbesartan/HCTZ · DIN 02372894 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418231 · $0.2281 Mint Irbesartan/HCTZ · DIN 02393018 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328526 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363216 · $0.2281 Sandoz Irbesartan HCT · DIN 02337436 · $0.2281
Shortage status: resolved shortage (ended 2024-06-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330520
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Irbesartan HCTZ · DIN 02330539 · 300mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Irbesartan HCTZ · DIN 02330539 Manufacturer: Teva Canada Limited; listing date 2011-08-04 Health Canada: Marketed since 2018-06-13 · brand TEVA-IRBESARTAN HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, IRBESARTAN 300 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Irbesartan HCTZ: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2184 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81626 · Verify on the e-Formulary ↗ (DIN 02330539)

Source record
DIN 02330539: Teva-Irbesartan HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800263; group id 331; item number 0742; lccId None; manufacturer id TEV Source form: Tab; strength: 300mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2184; ministry $0.2184 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02330539 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81626
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387662 · $0.2184 Auro-Irbesartan HCT · DIN 02447894 · $0.2184 Avalide · DIN 02280213 · not recorded Co Irbesartan/HCT · DIN 02357410 · $0.2184 Irbesartan HCT · DIN 02385333 · $0.2184 Irbesartan/HCTZ · DIN 02372908 · $0.2184 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418258 · $0.2184 Mint Irbesartan/HCTZ · DIN 02393026 · $0.2184 PMS-Irbesartan-HCTZ · DIN 02328534 · $0.2184 Ran-Irbesartan HCTZ · DIN 02363224 · $0.2184 Sandoz Irbesartan HCT · DIN 02337444 · $0.2184
Shortage status: discontinued (2024-06-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330539
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Irbesartan/HCTZ · DIN 02387646 · 150mg & 12.5mg · tablet

General benefitDormant since 2019-05-31 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Irbesartan/HCTZ · DIN 02387646 Manufacturer: Apotex Inc.; listing date 2013-03-20 Health Canada: Dormant since 2019-05-31 · brand APO-IRBESARTAN/HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 150 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Irbesartan/HCTZ: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87323 · Verify on the e-Formulary ↗ (DIN 02387646)

Source record
DIN 02387646: Apo-Irbesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id APX Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387646 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87323
Interchangeable products
Auro-Irbesartan HCT · DIN 02447878 · $0.2281 Avalide · DIN 02241818 · $0.2281 Co Irbesartan/HCT · DIN 02357399 · $0.2281 Irbesartan HCT · DIN 02385317 · $0.2281 Irbesartan/HCTZ · DIN 02372886 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328518 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Sandoz Irbesartan HCT · DIN 02337428 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330512 · $0.2281
Shortage status: discontinued (2018-07-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387646
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2019-05-31 — choose a marketed DIN from the same-category list.

Auro-Irbesartan HCT · DIN 02447878 · 150mg & 12.5mg · tablet

General benefitDormant since 2020-07-24 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Irbesartan HCT · DIN 02447878 Manufacturer: Auro Pharma Inc.; listing date 2017-07-31 Health Canada: Dormant since 2020-07-24 · brand AURO-IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 150 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Irbesartan HCT: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93350 · Verify on the e-Formulary ↗ (DIN 02447878)

Source record
DIN 02447878: Auro-Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id AUR Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447878 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93350
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387646 · $0.2281 Avalide · DIN 02241818 · $0.2281 Co Irbesartan/HCT · DIN 02357399 · $0.2281 Irbesartan HCT · DIN 02385317 · $0.2281 Irbesartan/HCTZ · DIN 02372886 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328518 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Sandoz Irbesartan HCT · DIN 02337428 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330512 · $0.2281
Shortage status: active shortage (reported 2018-10-17, last updated 2018-10-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447878
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2020-07-24 — choose a marketed DIN from the same-category list.

Irbesartan/HCTZ · DIN 02372886 · 150mg & 12.5mg · tablet

General benefitDormant since 2026-07-23 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Irbesartan/HCTZ · DIN 02372886 Manufacturer: Sanis Health Inc.; listing date 2020-10-30 Health Canada: Dormant since 2026-07-23 · brand IRBESARTAN/HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, IRBESARTAN 150 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Irbesartan/HCTZ: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85799 · Verify on the e-Formulary ↗ (DIN 02372886)

Source record
DIN 02372886: Irbesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id SAI Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372886 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85799
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387646 · $0.2281 Auro-Irbesartan HCT · DIN 02447878 · $0.2281 Avalide · DIN 02241818 · $0.2281 Co Irbesartan/HCT · DIN 02357399 · $0.2281 Irbesartan HCT · DIN 02385317 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328518 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Sandoz Irbesartan HCT · DIN 02337428 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330512 · $0.2281
Shortage status: active shortage (reported 2024-11-18, last updated 2024-11-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02372886
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-23 — choose a marketed DIN from the same-category list.

Apo-Irbesartan/HCTZ · DIN 02387654 · 300mg & 12.5mg · tablet

General benefitDormant since 2019-05-29 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Irbesartan/HCTZ · DIN 02387654 Manufacturer: Apotex Inc.; listing date 2013-03-20 Health Canada: Dormant since 2019-05-29 · brand APO-IRBESARTAN/HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 300 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Irbesartan/HCTZ: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87324 · Verify on the e-Formulary ↗ (DIN 02387654)

Source record
DIN 02387654: Apo-Irbesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800243; group id 331; item number 0741; lccId None; manufacturer id APX Source form: Tab; strength: 300mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387654 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87324
Interchangeable products
Auro-Irbesartan HCT · DIN 02447886 · $0.2281 Avalide · DIN 02241819 · $0.2281 Co Irbesartan/HCT · DIN 02357402 · $0.2281 Irbesartan HCT · DIN 02385325 · $0.2281 Irbesartan/HCTZ · DIN 02372894 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418231 · $0.2281 Mint Irbesartan/HCTZ · DIN 02393018 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328526 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363216 · $0.2281 Sandoz Irbesartan HCT · DIN 02337436 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330520 · $0.2281
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387654
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2019-05-29 — choose a marketed DIN from the same-category list.

Apo-Irbesartan/HCTZ · DIN 02387662 · 300mg & 25mg · tablet

General benefitDormant since 2019-08-02 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Irbesartan/HCTZ · DIN 02387662 Manufacturer: Apotex Inc.; listing date 2013-03-20 Health Canada: Dormant since 2019-08-02 · brand APO-IRBESARTAN/HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 300 MG, HYDROCHLOROTHIAZIDE 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Irbesartan/HCTZ: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2184 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87325 · Verify on the e-Formulary ↗ (DIN 02387662)

Source record
DIN 02387662: Apo-Irbesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800263; group id 331; item number 0742; lccId None; manufacturer id APX Source form: Tab; strength: 300mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2184; ministry $0.2184 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387662 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87325
Interchangeable products
Auro-Irbesartan HCT · DIN 02447894 · $0.2184 Avalide · DIN 02280213 · not recorded Co Irbesartan/HCT · DIN 02357410 · $0.2184 Irbesartan HCT · DIN 02385333 · $0.2184 Irbesartan/HCTZ · DIN 02372908 · $0.2184 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418258 · $0.2184 Mint Irbesartan/HCTZ · DIN 02393026 · $0.2184 PMS-Irbesartan-HCTZ · DIN 02328534 · $0.2184 Ran-Irbesartan HCTZ · DIN 02363224 · $0.2184 Sandoz Irbesartan HCT · DIN 02337444 · $0.2184 Teva-Irbesartan HCTZ · DIN 02330539 · $0.2184
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387662
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2019-08-02 — choose a marketed DIN from the same-category list.

Auro-Irbesartan HCT · DIN 02447886 · 300mg & 12.5mg · tablet

General benefitDormant since 2020-07-24 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Irbesartan HCT · DIN 02447886 Manufacturer: Auro Pharma Inc.; listing date 2017-07-31 Health Canada: Dormant since 2020-07-24 · brand AURO-IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 300 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Irbesartan HCT: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93351 · Verify on the e-Formulary ↗ (DIN 02447886)

Source record
DIN 02447886: Auro-Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800243; group id 331; item number 0741; lccId None; manufacturer id AUR Source form: Tab; strength: 300mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447886 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93351
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387654 · $0.2281 Avalide · DIN 02241819 · $0.2281 Co Irbesartan/HCT · DIN 02357402 · $0.2281 Irbesartan HCT · DIN 02385325 · $0.2281 Irbesartan/HCTZ · DIN 02372894 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418231 · $0.2281 Mint Irbesartan/HCTZ · DIN 02393018 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328526 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363216 · $0.2281 Sandoz Irbesartan HCT · DIN 02337436 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330520 · $0.2281
Shortage status: active shortage (reported 2018-09-17, last updated 2018-10-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447886
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2020-07-24 — choose a marketed DIN from the same-category list.

Auro-Irbesartan HCT · DIN 02447894 · 300mg & 25mg · tablet

General benefitDormant since 2020-07-24 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Irbesartan HCT · DIN 02447894 Manufacturer: Auro Pharma Inc.; listing date 2017-07-31 Health Canada: Dormant since 2020-07-24 · brand AURO-IRBESARTAN HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 25 MG, IRBESARTAN 300 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Irbesartan HCT: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2184 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93352 · Verify on the e-Formulary ↗ (DIN 02447894)

Source record
DIN 02447894: Auro-Irbesartan HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800263; group id 331; item number 0742; lccId None; manufacturer id AUR Source form: Tab; strength: 300mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2184; ministry $0.2184 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447894 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93352
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387662 · $0.2184 Avalide · DIN 02280213 · not recorded Co Irbesartan/HCT · DIN 02357410 · $0.2184 Irbesartan HCT · DIN 02385333 · $0.2184 Irbesartan/HCTZ · DIN 02372908 · $0.2184 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418258 · $0.2184 Mint Irbesartan/HCTZ · DIN 02393026 · $0.2184 PMS-Irbesartan-HCTZ · DIN 02328534 · $0.2184 Ran-Irbesartan HCTZ · DIN 02363224 · $0.2184 Sandoz Irbesartan HCT · DIN 02337444 · $0.2184 Teva-Irbesartan HCTZ · DIN 02330539 · $0.2184
Shortage status: active shortage (reported 2018-10-17, last updated 2018-10-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447894
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2020-07-24 — choose a marketed DIN from the same-category list.

Irbesartan/HCTZ · DIN 02372894 · 300mg & 12.5mg · tablet

General benefitDormant since 2026-07-23 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Irbesartan/HCTZ · DIN 02372894 Manufacturer: Sanis Health Inc.; listing date 2021-10-29 Health Canada: Dormant since 2026-07-23 · brand IRBESARTAN/HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, IRBESARTAN 300 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Irbesartan/HCTZ: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85800 · Verify on the e-Formulary ↗ (DIN 02372894)

Source record
DIN 02372894: Irbesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800243; group id 331; item number 0741; lccId None; manufacturer id SAI Source form: Tab; strength: 300mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372894 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85800
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387654 · $0.2281 Auro-Irbesartan HCT · DIN 02447886 · $0.2281 Avalide · DIN 02241819 · $0.2281 Co Irbesartan/HCT · DIN 02357402 · $0.2281 Irbesartan HCT · DIN 02385325 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418231 · $0.2281 Mint Irbesartan/HCTZ · DIN 02393018 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328526 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363216 · $0.2281 Sandoz Irbesartan HCT · DIN 02337436 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330520 · $0.2281
Shortage status: active shortage (reported 2024-10-07, last updated 2024-10-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02372894
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-23 — choose a marketed DIN from the same-category list.

Irbesartan/HCTZ · DIN 02372908 · 300mg & 25mg · tablet

General benefitDormant since 2026-07-23 · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Irbesartan/HCTZ · DIN 02372908 Manufacturer: Sanis Health Inc.; listing date 2020-10-30 Health Canada: Dormant since 2026-07-23 · brand IRBESARTAN/HCTZ · ATC C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 300 MG, HYDROCHLOROTHIAZIDE 25 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Irbesartan/HCTZ: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2184 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85801 · Verify on the e-Formulary ↗ (DIN 02372908)

Source record
DIN 02372908: Irbesartan/HCTZ Raw flags: chronicUseMed=Y, sec3=Y Item: 240800263; group id 331; item number 0742; lccId None; manufacturer id SAI Source form: Tab; strength: 300mg & 25mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2184; ministry $0.2184 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372908 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85801
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387662 · $0.2184 Auro-Irbesartan HCT · DIN 02447894 · $0.2184 Avalide · DIN 02280213 · not recorded Co Irbesartan/HCT · DIN 02357410 · $0.2184 Irbesartan HCT · DIN 02385333 · $0.2184 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418258 · $0.2184 Mint Irbesartan/HCTZ · DIN 02393026 · $0.2184 PMS-Irbesartan-HCTZ · DIN 02328534 · $0.2184 Ran-Irbesartan HCTZ · DIN 02363224 · $0.2184 Sandoz Irbesartan HCT · DIN 02337444 · $0.2184 Teva-Irbesartan HCTZ · DIN 02330539 · $0.2184
Shortage status: active shortage (reported 2024-06-01, last updated 2024-06-06) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02372908
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-23 — choose a marketed DIN from the same-category list.

Co Irbesartan/HCT · DIN 02357399 · 150mg & 12.5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.Discontinued 2018-06-12 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Co Irbesartan/HCT · DIN 02357399 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2011-08-04 Health Canada: Cancelled post market since 2018-06-12 · brand ACT IRBESARTAN/HCT · ATC C09DA04 IRBESARTAN AND DIURETICS, C09DA04 IRBESARTAN AND DIURETICS · form Tablet · route Oral · ingredients IRBESARTAN 150 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Actavis pharma company · schedule Prescription
Check this DIN again · Health Canada product record

Co Irbesartan/HCT: Formulary list price $0.2281/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2281 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84252 · Verify on the e-Formulary ↗ (DIN 02357399)

Source record
DIN 02357399: Co Irbesartan/HCT Raw flags: chronicUseMed=Y, sec3=Y Item: 240800242; group id 331; item number 0740; lccId None; manufacturer id COB Source form: Tab; strength: 150mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2281; ministry $0.2281 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357399 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84252
Interchangeable products
Apo-Irbesartan/HCTZ · DIN 02387646 · $0.2281 Auro-Irbesartan HCT · DIN 02447878 · $0.2281 Avalide · DIN 02241818 · $0.2281 Irbesartan HCT · DIN 02385317 · $0.2281 Irbesartan/HCTZ · DIN 02372886 · $0.2281 Jamp-Irbesartan and Hydrochlorothiazide · DIN 02418223 · $0.2281 Mint Irbesartan/HCTZ · DIN 02392992 · $0.2281 PMS-Irbesartan-HCTZ · DIN 02328518 · $0.2281 Ran-Irbesartan HCTZ · DIN 02363208 · $0.2281 Sandoz Irbesartan HCT · DIN 02337428 · $0.2281 Teva-Irbesartan HCTZ · DIN 02330512 · $0.2281
Shortage status: discontinued (2018-02-28, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357399
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE

· 34 products · General benefit · strengths: 100mg & 12.5mg, 50mg & 12.5mg, 100mg & 25mg · Tab

OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE

· 27 products · General benefit · strengths: 20mg & 12.5mg, 40mg & 12.5mg, 40mg & 25mg · Tab

TELMISARTAN & HYDROCHLOROTHIAZIDE

· 22 products · General benefit · strengths: 80mg & 12.5mg, 80mg & 25mg · Tab

VALSARTAN & HYDROCHLOROTHIAZIDE

· 34 products · General benefit · strengths: 80mg & 12.5mg, 160mg & 12.5mg, 160mg & 25mg, 320mg & 12.5mg, 320mg & 25mg · Tab

EPROSARTAN MESYLATE & HYDROCHLOROTHIAZIDE

· 1 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 600mg & 12.5mg · Tab

TELMISARTAN & AMLODIPINE BESYLATE

· 8 products · General benefit · strengths: 40mg & 10mg, 40mg & 5mg, 80mg & 10mg, 80mg & 5mg · Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications AVALIDE® (irbesartan/hydrochlorothiazide) is indicated: • for the treatment of essential hypertension in patients for whom combination therapy is appropriate (see DOSAGE AND ADMINISTRATION). • as initial therapy in patients with severe essential hypertension (Sitting DBP ≥ 110 mmHg) for whom the benefit of a prompt blood pressure reduction exceeds the risk of initiating combination therapy in these patients (see CLINICAL TRIALS and DOSAGE AND ADMINISTRATION). AVALIDE is not indicated as initial therapy in patients with mild to moderate essential hypertension. 1.1. Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of AVALIDE in patients <18 years of age have not been established. Therefore, Health Canada has not authorized an indication for pediatric use (see WARNINGS AND PRECAUTIONS, Special Populations). 1.2. Geriatrics Geriatrics (> 65 years of age): In clinical studies, no overall differences in safety or efficacy were observed between patients > 65 years of age and younger patients (see WARNINGS AND PRECAUTIONS, Special Populations). https://pdf.hres.ca/dpd_pm/00081257.PDF PM date: not printed or not captured Source product: AVALIDE; DIN 02241818; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

PMS-Irbesartan-HCTZ · DIN 02328518 Shortage status: active shortage (reported 2026-07-21, estimated to end 2027-01-31, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02328518

Check this DIN again

Sandoz Irbesartan HCT · DIN 02337428 Shortage status: active shortage (reported 2026-06-29, estimated to end 2026-10-09, last updated 2026-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337428

Check this DIN again

Teva-Irbesartan HCTZ · DIN 02330512 Shortage status: discontinued (2025-06-16, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330512

Check this DIN again

PMS-Irbesartan-HCTZ · DIN 02328526 Shortage status: active shortage (reported 2022-11-14, estimated to end 2026-12-01, last updated 2025-08-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02328526

Check this DIN again

Teva-Irbesartan HCTZ · DIN 02330539 Shortage status: discontinued (2024-06-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330539

Check this DIN again

Apo-Irbesartan/HCTZ · DIN 02387646 Shortage status: discontinued (2018-07-12, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387646

Check this DIN again

Auro-Irbesartan HCT · DIN 02447878 Shortage status: active shortage (reported 2018-10-17, last updated 2018-10-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447878

Check this DIN again

Irbesartan/HCTZ · DIN 02372886 Shortage status: active shortage (reported 2024-11-18, last updated 2024-11-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02372886

Check this DIN again

Apo-Irbesartan/HCTZ · DIN 02387654 Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387654

Check this DIN again

Apo-Irbesartan/HCTZ · DIN 02387662 Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02387662

Check this DIN again

Auro-Irbesartan HCT · DIN 02447886 Shortage status: active shortage (reported 2018-09-17, last updated 2018-10-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447886

Check this DIN again

Auro-Irbesartan HCT · DIN 02447894 Shortage status: active shortage (reported 2018-10-17, last updated 2018-10-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447894

Check this DIN again

Irbesartan/HCTZ · DIN 02372894 Shortage status: active shortage (reported 2024-10-07, last updated 2024-10-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02372894

Check this DIN again

Irbesartan/HCTZ · DIN 02372908 Shortage status: active shortage (reported 2024-06-01, last updated 2024-06-06) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02372908

Check this DIN again

Co Irbesartan/HCT · DIN 02357399 Shortage status: discontinued (2018-02-28, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357399

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)